← Leaderboards
Grinu Mathew
University Of Nebraska Medical Center
$2,591,510
Attributed
$2,591,510
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $983.2K · FY2022–25$1M$750K$500K$250K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,591,510 · 3
By mechanism
R01$1,379,946 · 1
P20$1,211,564 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Nebraska Medical Center
Same institution · by research overlap
- Raymond C Bergan$7,632,509
- Amarnath Natarajan$8,497,174
- Alexander V Kabanov$28,176,125
- Ravi Salgia$9,622,551
- Robert E. Lewis$14,454,663
Others in their field
Other Rising Stars on “Malignant Neoplasm Of Prostate”
- Javier Caravaca · University Of California, San Francisco$3,728,080
- Mirabela Rusu · Stanford University$2,887,122
- Remi Adelaiye-Ogala · State University Of New York At Buffalo$2,864,216
- Akash Patnaik · University Of Chicago$2,630,502
- Clinton David Bahler · Indiana University Indianapolis$2,408,587
- Megan K Ruhland · Oregon Health & Science University$2,265,578
Research focus
Malignant Neoplasm Of ProstateMalignant NeoplasmsMouse ModelCellsSignal TransductionProstate Cancer MetastasisReceptorNeoplasm MetastasisReceptor SignalingMetastatic Prostate CancerGrowthIn VivoCancer PatientGeneticStandard Of CareClinical TranslationProstateMediatingAndrogen Deprivation TherapyMolecularResistanceIndolentInhibitorGenotype
Grant awards (7)
Leveraging PMN immune response to overcome ADT resistance in bone metastatic prostate cancer$702,262
R01 · FY2025 · CA · contact PI
Defining and Characterizing Drivers of Lethal Metastatic Prostate Cancer$280,905
P20 · FY2025 · GM · contact PI
Leveraging PMN immune response to overcome ADT resistance in bone metastatic prostate cancer$333,575
R01 · FY2024 · CA · contact PI
Defining and Characterizing Drivers of Lethal Metastatic Prostate Cancer$280,905
P20 · FY2024 · GM · contact PI
Leveraging PMN immune response to overcome ADT resistance in bone metastatic prostate cancer$344,109
R01 · FY2023 · CA · contact PI
Defining and Characterizing Drivers of Lethal Metastatic Prostate Cancer$280,905
P20 · FY2023 · GM · contact PI
Defining and Characterizing Drivers of Lethal Metastatic Prostate Cancer$368,849
P20 · FY2022 · GM · contact PI